Date of publication: October 15, 2020
- To search and summarize available evidence on the clinical efficacy and effectiveness of PCV10 and PCV13 in preventing IPD, pneumonia and AOM, inducing immune response, and lowering pneumococcal nasopharyngeal carriage
- To determine which PCV represents good value for money in the Philippines for preventing mortality and morbidity due to IPD, clinical pneumonia, and AOM for children under 1 year
- To determine the budget implication of immunizing infants with PCV 10 or PCV 13 in the Expanded Program on Immunization (EPI)
- To identify the ethical, legal, social, and health system implications (ELSHSI) of immunizing infants with either PCV10 or PCV13 to prevent mortality and morbidity due to IPD, clinical pneumonia, and AOM.
HTA Full Report: http://bit.ly/PCVreassessmentFULLREPORT
Evidence summary: https://bit.ly/3mn0Nd4